results

New Blood Test Shows‌ Promise​ in Early Bladder Cancer Detection, Boosting Survival Rates

Milan, Italy‌ – October 20, 2025 – A novel‌ blood test demonstrating high accuracy in ‍detecting early-stage bladder cancer is poised to significantly improve patient⁤ outcomes, offering a less invasive alternative ⁤to conventional cystoscopies.Researchers at ⁣the European institute of Oncology‍ (IEO) in⁤ Milan announced today the results‍ of a multi-center clinical trial revealing the test’s ability​ to identify the‍ disease with up to 85% sensitivity and​ 90% specificity. This breakthrough could dramatically alter the landscape of bladder cancer diagnosis and treatment, possibly leading to earlier interventions and increased survival rates ​for⁢ the approximately 430,000 people diagnosed with the‌ disease globally each year.

Bladder cancer, frequently enough initially presenting with subtle symptoms like blood in the ‍urine, frequently‌ isn’t ​diagnosed until‌ it has progressed to a ⁤more advanced stage. This late detection‌ contributes to a five-year survival rate of approximately 77% in the united States,a figure experts believe ​could be substantially improved⁢ with ⁤earlier diagnosis. The‌ new ​blood test analyzes circulating tumor DNA (ctDNA)‌ – ‍fragments of cancer cells’ genetic material released into ​the bloodstream – offering a non-invasive method to identify the⁣ presence of the disease,even before symptoms manifest. The IEO study, published in ‍ The Lancet oncology, ⁣followed 500 patients ⁣with suspected ​bladder cancer and ​500 healthy controls, demonstrating ‍the test’s robust performance across diverse patient⁣ populations. ⁣ Researchers anticipate the‍ test ‌will initially⁢ be used to triage patients, ⁤reducing the number​ of​ needless cystoscopies – a procedure⁢ frequently enough considered ‌uncomfortable and requiring specialized equipment – and focusing ⁣them on individuals with a higher probability of having the disease.